Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival ...
Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, ...
Abemaciclib can improve progression-free survival in patients with advanced dedifferentiated liposarcoma, researchers report.
Dedifferentiated liposarcoma (DDLS) is a rare and aggressive soft tissue cancer with few effective treatment options. But now ...
Eli Lilly's Verzenio could offer the first targeted therapy for dedifferentiated liposarcoma (DDLPS), an aggressive cancer that usually needs to be treated with chemotherapy, according to the results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results